Table 1 Clinical & Laboratory Characteristics of Patients

Age (years)

38

65

62

Sex

Female

Female

Female

IHC lymphoma subtype

GCB

GCB

Non-GCB

Phenotypes

CD5(+), CD10(+), Bcl-2(+), Bcl-6(+), CD20(+), CD3(+), MUM-1(−), CD7(+), CycinD1(−)

CD5(+), CD10(−), Bcl-2(+), Bcl-6(+), CD20(+), CD3(+), MUM-1(+), PAX-5(+), CD68(−), CycinD1(−)

CD5(+), CD10(−), Bcl-6(+), CD20(+), CD3(−), MUM-1(+), CD56(−), CycinD1(−)

B symptoms

Y

Y

N

Fever

Y

Y

N

Night sweats

Y

N

N

Weight loss

Y

N

N

Bulky disease (> 7.5 cm)

N

N

N

> 2 extranodal sites

Y (terminal ileum, stomach, liver)

Y (colon, chest wall)

Y (neck region, nasopharynx)

LDH (120–250 U/L)

5233

245.5

267.9

β2-microglobulin (1.0–3.0 mg/L)

3.4

3.39

1.5

Ki-67

70%

80%

50%

Stage

IV

IV

III

R-IPI prognostic group

5

3

4

Bone marrow involvement

N

N

N

Complications

Malnutrition sinus Tachycardia

Pulmonary infection

Cholecystitis

Hypertension

T2DM

Treatment

R-CHOPx3(PR) → R-CHOPx1 (PD) → R-Gemoxx2(NR)

R-CHOPx4(PR) → R-CHOPx3(SD) → R-Gemoxx4(PR) → R-IMVP16(NR)

R-CHOPx3(NR) → DICE (NR) → R-DHAPx2(PD)